Welcome to our dedicated page for Third Harmonic Bio SEC filings (Ticker: THRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Third Harmonic Bio, Inc. (THRD) used its SEC filings to report both its clinical-stage biopharmaceutical activities and, later, its transition into liquidation and dissolution. Before adopting its Plan of Dissolution, the company’s periodic reports and related filings described a business focused on developing novel, highly selective, small-molecule inhibitors of KIT for dermal, respiratory, and gastrointestinal inflammatory diseases, with THB335 as its lead oral KIT inhibitor candidate.
In its annual and quarterly reports, Third Harmonic Bio provided details on the THB335 program, including Phase 1 single and multiple ascending dose trial design, safety and tolerability findings, pharmacokinetic characteristics such as once-daily dosing potential, and pharmacodynamic effects measured by reductions in serum tryptase. These filings also discussed the termination of the earlier THB001 program, research and development expense trends, and the company’s cash and cash equivalents position. Investors used these documents to understand the company’s clinical development plans, including Phase 2 readiness in chronic spontaneous urticaria.
Later filings focus on corporate restructuring and dissolution. An 8-K filed July 21, 2025 described Third Harmonic Bio’s intention to voluntarily delist its common stock from The Nasdaq Stock Market and deregister under Section 12(b) of the Exchange Act in connection with a previously approved Plan of Liquidation and Dissolution. An 8-K filed July 31, 2025 reported that the company filed a Certificate of Dissolution with the Secretary of State of the State of Delaware, effective upon filing, fixed a record date for liquidation distributions, and instructed its transfer agent to close its stock transfer books.
On July 31, 2025, Third Harmonic Bio filed a Form 25 to effect the voluntary delisting of its common stock from Nasdaq, with delisting effective on or about August 10, 2025. On August 11, 2025, the company filed a Form 15 to terminate registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and to suspend its reporting obligations under Sections 13 and 15(d). These filings formally document the end of THRD as a listed, reporting issuer.
On this page, Stock Titan surfaces Third Harmonic Bio’s SEC filings, including 10-K and 10-Q reports, 8-K current reports detailing material events such as the Plan of Dissolution and delisting steps, and Forms 25 and 15 related to Nasdaq removal and deregistration. AI-powered summaries help explain the implications of complex documents, highlight key clinical and financial disclosures, and clarify the sequence of events leading to liquidation, providing a structured view of THRD’s regulatory history.
Third Harmonic Bio, Inc. (THRD) filed Post-Effective Amendment No. 1 to four Form S-8 registration statements in order to deregister all unsold shares that were previously registered under its 2019 Stock Incentive Plan, 2022 Equity Incentive Plan and 2022 Employee Stock Purchase Plan. The affected filings (Nos. 333-267445, 333-270935, 333-278232 and 333-286189) had collectively covered ≈15.4 million shares of common stock.
The action stems from the company’s Plan of Dissolution, approved by the board on 10-Apr-2025 and by shareholders on 5-Jun-2025. A Certificate of Dissolution became effective 31-Jul-2025, officially placing the company in liquidation and terminating all offerings under the Securities Act. Pursuant to Rule 478, only CFO & Business Officer Christopher Murphy signed the amendments.
No operating or financial data are provided; the filing strictly notifies investors that equity incentive and ESPP shares will no longer be issued.
Third Harmonic Bio, Inc. (THRD) has filed Post-Effective Amendment No. 1 to four previously effective Form S-8 registration statements (File Nos. 333-267445, 333-270935, 333-278232 and 333-286189). The amendments deregister all shares of common stock that remain unsold under the company’s 2019 Stock Incentive Plan, 2022 Equity Incentive Plan and 2022 Employee Stock Purchase Plan.
The action follows the company’s wind-down: the board adopted a Plan of Dissolution on Apr 10 2025, shareholders approved it on Jun 5 2025, and a Certificate of Dissolution was filed on Jul 31 2025, becoming effective immediately. In line with the plan, THRD has terminated all securities offerings and is amending the S-8 filings to remove any unsold securities from registration. The amendment was signed by Chief Financial & Business Officer Christopher Murphy; no additional signatures are required under Rule 478.